Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy ...

The study participants reflected a diverse population of MASH patients. About 56% had type 2 diabetes, and approximately 73% were classified as obese. This suggests that semaglutide may be ...

This is the first regulatory-level trial showing the benefit of semaglutide for people with MASH. The trial is led by two chief investigators, Professor Philip Newsome at King's College London and ...

Researchers chose to investigate semaglutide as a potential treatment because this class of drug has previously been shown to reduce fat and liver scarring for people with MASH. Between 2021 and ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...